Chemical subgroup
L01EX – Andere Proteinkinase-Inhibitoren
45Decisions
63Patient groups
Added benefit by patient group
- Major2
- Considerable5
- Minor5
- Non-quantifiable2
- Not proven49
Decisions, newest first
- 2026-06-18RetsevmoSelpercatinibNot proven: 2 of 2 patient groups
- 2026-05-07AyvakytAvapritinibMinor
- 2026-04-16AyvakytAvapritinibNot proven
- 2026-04-16AyvakytAvapritinibNot proven
- 2026-04-16RomvimzaVimseltinibConsiderable
- 2025-11-20RetsevmoSelpercatinibMajor
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-10-16AugtyroRepotrectinibNot proven: 3 of 3 patient groups
- 2025-08-07OfevNintedanibNot proven
- 2025-08-07OfevNintedanibNot proven
- 2025-04-03TruqapCapivasertibConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-11-07RetsevmoSelpercatinibNot proven: 2 of 2 patient groups
- 2024-08-01VanflytaQuizartinibNot proven
- 2024-05-02RydaptMidostaurinNot proven
- 2024-05-02RydaptMidostaurinNot proven
- 2024-02-06RozlytrekEntrectinibNot proven
- 2022-12-01Cabometyx CabozantinibNot proven
- 2022-07-07LenvimaLenvatinibConsiderable
- 2022-07-07KisplyxLenvatinibNot proven: 2 of 2 patient groups
- 2022-06-16QinlockRipretinibMajor
- 2022-06-16GavretoPralsetinibNot proven: 5 of 5 patient groups
- 2022-03-18CaprelsaVandetanibNot proven
- 2021-12-16CometriqCabozantinibNon-quantifiable
- 2021-10-21Cabometyx CabozantinibNot proven: 2 of 2 patient groups
- 2021-09-02RetsevmoSelpercatinibNot proven
- 2021-09-02RetsevmoSelpercatinibNot proven
- 2021-09-02RetsevmoSelpercatinibNot proven: 3 of 3 patient groups
- 2021-07-01KisplyxLenvatinibNot proven
- 2021-02-18RozlytrekEntrectinibNot proven
- 2021-02-18RozlytrekEntrectinibNot proven
- 2021-02-04OfevNintedanibMinor
- 2021-02-04OfevNintedanibNot proven
- 2020-05-14XospataGilteritinibConsiderable
- 2020-04-02VitrakviLarotrectinibNot proven
- 2019-10-17OfevNintedanibConsiderable
- 2019-08-15LenvimaLenvatinibNot proven
- 2019-06-06Cabometyx CabozantinibMinor
- 2019-03-22LenvimaLenvatinibNot proven: 2 of 2 patient groups
- 2018-12-06Cabometyx CabozantinibNot proven: 2 of 2 patient groups
- 2018-04-05Cabometyx CabozantinibMinor
- 2017-07-06CaprelsaVandetanibNon-quantifiable
- 2016-03-17StivargaRegorafenibNot proven
- 2015-06-18VargatefNintedanibMinor
- 2015-02-19StivargaRegorafenibNot proven
Data status: 2026-10-29